MediSix Therapeutics is an early-stage cell therapy company that is taking a novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T cell lymphoma and leukemia.
Location: Singapore
Investors 1
| Date | Name | Website |
| 06.04.2022 | Lightstone... | lightstone... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 15.09.2022 | ClavystBio... | ClavystBio will invest and wor... | - | - | en.prnasia... |